Article

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells

2022-12-28

Abstract excerpt

<title>Abstract</title> <p>Mutant TP53 proteins are thought to drive the development and sustained expansion of cancers at least in part through the loss of the wild-type (wt) TP53 tumour suppressive functions. Therefore, compounds that can restore wt TP53 functions in mutant TP53 proteins are expected to inhibit the expansion of tumours expressing mutant TP53. APR-246 has been reported to exert such effects in m...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 22a60dda-34e5-5240-9868-a62f691197c6
DOI: 10.21203/rs.3.rs-2372230/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cellsDOI 10.21203/rs.3.rs-2372230/v1Read

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.Semantic proximity Read

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.Semantic proximity Read

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53Semantic proximity Read

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer TherapySemantic proximity Read

APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti-PD-1 efficacy in bladder cancer.Semantic proximity Read

APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.Semantic proximity Read

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.Semantic proximity Read

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.Semantic proximity Read

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsSemantic proximity Read

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer CellsSemantic proximity Read

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemiaSemantic proximity Read

APR-246 Enhances Colorectal Cancer Sensitivity to RadiotherapySemantic proximity Read